Changeflow GovPing Healthcare & Life Sciences USPTO Patent Application: Neuronal Migration Pr...
Routine Notice Added Final

USPTO Patent Application: Neuronal Migration Promoter for Brain Disease Treatment

Favicon for changeflow.com USPTO Patent Applications - Pharma (A61K)
Published
Detected
Email

Summary

The USPTO has published a patent application (US20260083761A1) from Public University Corporation Nagoya City University for a pharmaceutical composition and method to promote neuronal migration for treating brain diseases. The application details the use of a neuraminidase inhibitor.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a USPTO patent application (US20260083761A1) filed on September 8, 2023, by Public University Corporation Nagoya City University. The application describes a pharmaceutical composition, a neuronal migration promoter, and a method for treating brain diseases by using a neuraminidase inhibitor to promote the migration of neurons. The abstract highlights the potential of this technology for neurological treatments.

As this is a patent application, it does not impose immediate compliance obligations on regulated entities. However, companies involved in pharmaceutical research and development, particularly in the area of neuroscience and brain disease treatment, should monitor the progress of this patent application and related technologies. The assignee and inventors are listed as Public University Corporation Nagoya City University, Kazunobu Sawamoto, and Mami Matsumoto.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

PHARMACEUTICAL COMPOSITION FOR TREATING BRAIN DISEASE, NEURONAL MIGRATION PROMOTER, AND USE THEREOF

Application US20260083761A1 Kind: A1 Mar 26, 2026

Assignee

PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY

Inventors

Kazunobu SAWAMOTO, Mami MATSUMOTO

Abstract

Provided is a technology capable of promoting migration of neurons. This pharmaceutical composition for treating a brain disease includes a neuraminidase inhibitor, this neuronal migration promoter includes a neuraminidase inhibitor, and this method of promoting migration of neurons includes a step of bringing a neuraminidase inhibitor into contact with neurons.

CPC Classifications

A61K 31/7012 A61K 9/0019 A61P 25/00

Filing Date

2023-09-08

Application No.

19110266

View original document →

Named provisions

PHARMACEUTICAL COMPOSITION FOR TREATING BRAIN DISEASE, NEURONAL MIGRATION PROMOTER, AND USE THEREOF

Get daily alerts for USPTO Patent Applications - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
September 8th, 2023
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260083761A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
R&D
Compliance frameworks
GxP
Topics
Medical Devices Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!